Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



For Sale, Just Not at That Price

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Scratch the "or best offer" from Human Genome Sciences' (Nasdaq: HGSI  ) For Sale sign. The biotech is willing to be taken out, just not at the price GlaxoSmithKline (NYSE: GSK  ) is willing to pay.

Human Genome Sciences is partnered with Glaxo on their lupus drug Benlysta and has licensed a few other drugs to the pharma giant. The $13-per-share offer was flat-out rejected by Human Genome Sciences' board, but the board figured it should see if someone else is interested -- perhaps Glaxo at a higher price -- and is putting the company up for sale at the right price.

Glaxo is clearly in the best position to benefit from an acquisition of Human Genome Sciences; the pharma thinks it can achieve about $200 million of cost savings by 2015. And it's best able to value Human Genome Sciences since it has intimate knowledge of its drugs.

That doesn't mean that some pharma won't try and top Glaxo's bid. Eli Lilly (NYSE: LLY  ) outbid Bristol-Myers Squibb (NYSE: BMY  ) for its partner ImClone Systems. And Abbott Labs (NYSE: ABT  ) rescued Facet Biotech from the low offer made by its partner Biogen Idec. In both those cases, after upping its first lowball bid, the partner didn't get in a bidding war with the third party, arguing that the partner knows the true value -- or at least thinks it does.

Will another pharma be interested in topping Glaxo? Anything's possible, but I wouldn't hold my breath; there has to be some opportunity for the acquirer to drive value. Human Genome Sciences co-markets Benlysta with Glaxo, so a suitor might think it can increase sales through better marketing. But part of Human Genome Sciences' value is tied up in phase 3 drugs darapladib and albiglutide that Glaxo has licensed, and there's no opportunity for a third party to derive value there because they're under full control of Glaxo. The best an acquirer can hope for is royalty and milestone payments, but valuing those is tough from the outside.

Glaxo raising its bid is a better bet, but it's hard to justify buying with Human Genome Sciences trading substantially above the $13 bid. How high might Glaxo go given Benlysta's relatively slow launch? And will the board be willing to accept it given that the stock was trading near $30 per share this time last year? Unless you can confidently answer those two questions -- I can't -- I don't see much reason to buy at this point.

These three tech companies, on the other hand, aren't at the whim of executives bidding. Find out what they are and why Fool analysts think they'll do well in the new industrial revolution in our new free report.

Fool contributor Brian Orelli holds no position in any company mentioned. Click here to see his holdings and a short bio. The Motley Fool owns shares of Abbott Laboratories. Motley Fool newsletter services have recommended buying shares of GlaxoSmithKline. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.

Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1867225, ~/Articles/ArticleHandler.aspx, 10/25/2016 9:03:11 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,169.27 -53.76 -0.30%
S&P 500 2,143.16 -8.17 -0.38%
NASD 5,283.40 -26.43 -0.50%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/25/2016 4:02 PM
GSK $40.32 Down -0.36 -0.88%
GlaxoSmithKline CAPS Rating: ***
HGSI.DL $0.00 Down +0.00 +0.00%
Human Genome Scien… CAPS Rating: **
ABT $40.19 Down -0.22 -0.54%
Abbott Laboratorie… CAPS Rating: *****
BMY $49.55 Up +0.32 +0.65%
Bristol-Myers Squi… CAPS Rating: ****
LLY $77.75 Up +0.18 +0.23%
Eli Lilly and Co. CAPS Rating: ***